HomeEXECUTIVES

EXECUTIVES

Sanjay D Goorachurn New CEO at Medisca

Sanjay D Goorachurn is regarded as one of the world’s leading IP strategists working closely with senior executives of private and public companies on maximizing the commercial value of a company’s innovation and IP assets.

Frank Vizesi Appointed Chief Scientific Officer at Theradaptive | Strengthens Executive Team

Frank Vizesi brings over 20 years experience in cutting-edge orthobiologics research, with previous roles at NuVasive, SeaSpine and most recently as Chief Scientific Officer at Orthofix.

Cal Bontemps Appointed Radians Director of Marketing

Cal Bontemps brings a wealth of expertise to lead the marketing team while driving strategic alignment with Radians' sales goals and objectives.

CPR-Therapeutics Announces Mike Black as Chief Strategy Officer

Mike Black said, “I’m looking forward to advising the CPR Therapeutics team on the development of this important suite of medical technologies. I have a long-term commitment to improving the outcome of patients suffering cardiac arrest. CPR-T’s approach is a major opportunity to advance care and have a meaningful impact on one of the leading killers worldwide.”

Corinne Le Goff Appointed Viatris Chief Commercial Officer

Corinne Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally.

Julie Blasingim Promoted to Chief Executive Officer of Univo IRB

Julie Blasingim, formerly President, has over 20 years of experience in the clinical research industry.

John Witkowski Appointed President & CEO of Solesis

John Witkowski served as President of DSM Biomedical, the global biomaterials division of dsm-firmenich, where he led a significant period of transformational growth.

Julia James Appointed Clario Chief Legal and Administrative Officer

Julia James served as Executive Vice President and General Counsel of PPD, the leading contract research organization, until its acquisition by Thermo Fisher Scientific in 2021. She then continued as General Counsel, Clinical Research, following the transaction.

John Edwards Appointed PanTher Therapeutics Executive Chair of the Board of Directors

John Edwards brings over 35 years of experience in discovery, development, and global commercialization of biopharmaceuticals to PanTher. His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute.
Exit mobile version